Sglt2 Inhibitors Market Current And Projected Size In Terms Of Volume And Value 20162024 | Latest News RSS feed

Sglt2 Inhibitors Market Current And Projected Size In Terms Of Volume And Value 20162024 - Latest News


SGLT2 Inhibitors Market Current and Projected size in terms of volume and value 2016-2024

SGLT2 inhibitors are expected to have high consumption in the near future due to simple treatment ... Dapaglifozin has no generic brands available in the market and is marketed by Boehringer Ingelheim ... read more

Johnson & Johnson (JNJ) Q3 2016 Results - Earnings Call Transcript

Our R&D and commercial capabilities are a proven strong foundation for future growth. First, we will continue to focus on driving volume growth across our current market-leading brands ... Globally, i... read more

Sirona Biochem Corporation-CEO's Report on Progress

We raised $600,000 in debt which gave us the financial runway to grow the value ... term goals include setting up future pipeline projects and growing our R&D infrastructure. In the next 30 months we ... read more

Looking for another news?


Inovalon Reports Fourth Quarter and Full Year 2016 Results

Feb. 22, 2017 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq:INOV), a leading technology company providing advanced, cloud-based platforms empowering a data-driven transformation from volume-based to value-base... read more


Eli Lilly and : Lilly Reports Strong First-Quarter 2018 Results, Raises EPS Guidance

Lilly remains poised to deliver more innovation for patients and increased value for stakeholders ... in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of ... read more

How The Global Pharma Industry Will Shape Up In The Next 5 Years?

The emerging market continue to grow in mid teens and the size should double by 2018. Favorable Forces 1) R&D / New Drug Innovation 2) Austerity Measures to control costs 3) Emerging markets Growth Op... read more

Merck Announces Second-Quarter 2017 Financial Results

“The company continues to invest in innovative science that addresses the critical needs of population health, which benefits patients while creating long-term value for shareholders ... an investigat... read more

Pharmacotherapy for childhood obesity: present and future prospects

It is to be hoped that the future will bring new drugs targeting specific obesity ... ‘clinical trial’ or ‘review’ that was supplemented by manual searches for current and new drugs for adults (Table ... read more

Bristol-Myers Squibb's Management Discusses Q1 2013 Results - Earnings Call Transcript

BYDUREON sales volume and market ... at current rates, we would expect to see some pressure through the remainder of the year. So, taken together, this is an important time for Bristol-Myers Squibb. W... read more

Lilly Reports Strong First-Quarter 2018 Results, Raises EPS Guidance

Lilly remains poised to deliver more innovation for patients and increased value for stakeholders ... cell therapies for the potential treatment of type 1 diabetes. Under the terms of the agreement, L... read more

Convertible visceral fat as a therapeutic target to curb obesity

Approved drugs that have browning properties as well as future drugs that target molecular pathways involved ... possibly because of their developmental route and the reduced size at which they die, t... read more

Sirona Biochem Corporation-CEO's Report on Progress

Skip to Market Summary Skip to Main Content Skip to Related Content Sign in Finance Home Watchlists My Portfolio My Screeners Yahoo Originals Personal Finance Tech Market Data Industry News ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us